Management of the advanced phases of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors

Leukemia and Lymphoma

Volumn 50, Issue 1, 2009, Pages 14-23

  Martin, Mike G ^a   Dipersio, John F ^a   Uy, Geoffrey L ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Drug resistance; Myeloid leukemias and dysplasias; Signalling therapies

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ABELSON KINASE; ANTINEOPLASTIC AGENT; BORTEZOMIB; BOSUTINIB; CARBOPLATIN; CLOFARABINE; CYTARABINE; DASATINIB; DAUNORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; IDARUBICIN; IMATINIB; INTERFERON; METHYLPREDNISOLONE SODIUM SUCCINATE; MITOXANTRONE; NILOTINIB; PANOBINOSTAT; PHA 739358; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; TEMSIROLIMUS; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; VINCRISTINE; XL 228;

ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOPENIA; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG MEGADOSE; FEBRILE NEUTROPENIA; HUMAN; HYPERBILIRUBINEMIA; LEUKEMIA REMISSION; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; OVERALL SURVIVAL; PATIENT CARE PLANNING; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DOMAIN; REVIEW; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES;

EID: 59249090119     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802517765     Document Type: Review

References (79)

1. Deutsch, E., Dugray, A., Abdul Karim, B, Marangoni, E., Maggiorella, L. Vaganay, S. et al. (2001) BCR-ABL downregulates the DNA repair protein DNA-PKcs. Blood, 97, pp. 2084-2090.
2. Dierov, J., Dierova, R. and Carroll, M. (2004) BCR/ABL translocates to thenucleus and disrupts an ATR-dependent intra-S phase checkpoint. Cancer Cell, 5, pp. 275-285.
3. Sattler, M., Verma, S., Shrikhande, G., Byrne, C. H., Pride, Y. B. Winkler, T. et al. (2000) The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem, 275, pp. 24273-24278.
4. Canitrot, Y., Falinski, R., Louat, T., Laurent, G., Cazaux, C. Hoffmann, J. S. et al. (2003) p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation. Blood, 102, pp. 2632-2637.
5. Marktel, S., Marin, D., Foot, N., Szydlo, R., Bua, M. Karadimitris, A. et al. (2003) Chronic myeloid leukemia in chronic phase responding to imatinib: The occurrence of additional cytogenetic abnormalities predicts disease progression. Haematologica, 88, pp. 260-267.
6. Ilaria, R. L. (2005) Pathobiology of lymphoid and myeloid blast crisis and management issues. Hematology, pp. 188-194.
7. NCCN guidelines for Chronic Myeloid Leukema
8. Kantarjian, H. M., Keating, M. J., Talpaz, M., Walters, R. S., Smith, T. L. Cork, A. et al. (1987) Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med, 83, pp. 445-454.
9. Kantarjian, H., O'Brien, S., Cortes, J., Giles, F., Thomas, D. Kornblau, S. et al. (2003) Sudden onset of the blastic phase of chronic myelogenous leukemia: Patterns and implications. Cancer, 98, pp. 81-85.
10. O'Brien, S. O., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M. and Cervantes, F. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Eng J Med, 348, pp. 994-1004.
11. Ramirez, P. and DiPersio, J. F. (2008) Therapy options in imatinib failures. Oncologist, 13, pp. 424-434.
12. Branford, S., Rudzki, B., Lynch, K. and Hughes, T. (2005) Pre-imatinib factors can be used to define the risk of BCR-ABL mutations for patients with CML in chronic phase and identify a minority who should have regular mutation screening. Blood (ASH Annual Meeting Abstracts), 106, p. 1079.
13. Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F. Poerio, A. et al. (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res, 12, pp. 7374-7379.
14. de Lavallade, H., Apperly, J. F., Khorashad, J. S., Milojkovic, D., Reid, A. G. Bua, M. et al. (2008) Imatinib for newly diagnosed patients with chronic myeloid leukemia: Incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol, 26, pp. 3358-3363.
15. Druker, B., Guilhot, F., O'Brien, S., Gathmann, I., Kantarjian, H. Gattermann, N. et al. (2006) Five-year follow-up of imatinib therapy for newly diagnosed chronic myelogenous leukemia in chronic-phase shows sustained responses and high overall survival. N Engl J Med, 355, pp. 2408-2417.
16. Barone, S., Baer, M. R., Sait, S. N., Lawrence, D., Block, A. W. and Wetzler, M. (2001) High-dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. Am J Hematol, 67, pp. 119-124.
17. Anger, B. and Heimpel, H. (1989) Daunomycin, cytosine-arabinoside and VP-16 (DAV) for myeloid blast crisis of CML. Blut, 58, pp. 299-301.
18. Cervantes, F., Rozman, C., Blade, J., Montserrat, E. and Granena, A. (1985) Treatment of blast crisis of chronic myelogenous leukemia with vincristine, prednisone and cytarabine. Cancer Treat Rep, 69, pp. 923-924.
19. Dutcher, J. P., Wiernik, P. H. and Strauman, J. J. (1985) Mitoxantrone and cytosine arabinoside in acute non-lymphocytic leukemia and blast crisis of chronic myelogenous leukemia. Proc Am Soc Clin Oncol, 4, p. 170a.
20. Winton, E. F., Miller, D. and Vogler, W. R. (1981) Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia. Cancer Treat Rep, 65, pp. 389-392.
21. Liang, R., Chan, T. K., Chiu, E. and Todd, D. (1992) Non-aggressive therapy for chronic myeloid leukemia in blastic transformation. Cancer Chemother Pharmacol, 29, pp. 323-325.
22. Marsh, J. H., Kreis, W., Barile, B., Akerman, S., Schulman, P. Allen, S. L. et al. (1993) Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine and carboplatin. Cancer Chemother Pharmacol, 31, pp. 481-484.
23. Saito, Y., Uzuka, Y., Takahashi, H., Komatsu, M. and Ito, T. (1986) The treatment of chronic myelogenous leukemia in blastic crisis with the chemotherapy incorporating vindesine-prednisolone. Tohoku J Exp Med, 148, pp. 65-72.
24. Kouides, P. A. and Rowe, J. M. (1995) A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis. Leuk Res, 19, pp. 763-770.
25. Montefusco, E., Petti, M. C., Alimena, G., Latagliata, R., Celesti, F. Capria, S. et al. (1997) Etoposide, intermediate-dose cytarabine and carboplatin (VAC): A combination therapy for the blastic phase of chronic myelogenous leukemia. Ann Oncol, 8, pp. 175-179.
26. Schneller, F., Schuler, M., Schumacher, K., Thaler, J., Peschel, C. Huber, C. et al. (1998) Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia - results of a phase II trial. Ann Hematol, 77, pp. 225-229.
27. Spriggs, D. R., Robbins, G., Arthur, K., Mayer, R. J. and Kufe, D. (1988) Prolonged high dose ARA-C infusions in acute leukemia. Leukemia, 2, pp. 304-306.
28. Feldman, E. J., Alberts, D. S., Arlin, Z., Ahmed, T., Mittelman, A. Baskind, P. et al. (1993) Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia. J Clin Oncol, 11, pp. 2002-2009.
29. Kantarjian, H. M., Walters, R. S., Keating, M. J., Talpaz, M., Andersson, B. Beran, M. et al. (1988) Treatment of the blastic phase of chronic myelogenous leukemia with mitoxantrone and high-dose cytosine arabinoside. Cancer, 62, pp. 672-676.
30. Ernst, T. J., Rosenthal, D. S., Griffin, J. D. and Canellos, G. P. (1988) Treatment of the blastic phase of chronic myelogenous leukemia with high-dose cytosine arabinoside. Am J Clin Oncol, 11, pp. 623-626.
31. Iacoboni, S. J., Plunkett, W., Kantarjian, H. M., Estey, E., Keating, M. J. McCredie, K. B. et al. (1986) High-dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol, 4, pp. 1079-1088.
32. Kantarjian, H. M., Talpaz, M., Kontoyiannis, D., Gutterman, J., Keating, M. J. Estey, E. H. et al. (1992) Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor. J Clin Oncol, 10, pp. 398-405.
33. Koller, C. A., Kantarjian, H. M., Feldman, E. J., O'Brien, S., Rios, M. B. Estey, E. et al. (1999) A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia. Cancer, 86, pp. 2246-2251.
34. Kantarjian, H. M., O'Brien, S., Cortes, J., Giles, F. J., Faderl, S. Issa, J. P. et al. (2003) Results of decitabine (5-Aza-2-Deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer, 98, pp. 522-528.
35. Issa, J-PJ, Gharibyan, V., Cortes, J., Jelinek, J., Morris, G. and Verstovsek, S. (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol, 23, pp. 3948-3956.
36. Sacchi, S., Kantarjian, H. M., O'Brien, S., Cortes, J., Rios, M. B. Giles, F. J. et al. (1999) Chronic myelogenous leukemia in nonlymphoid blastic phase analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer, 86, pp. 2632-2641.
37. Druker, B. J., Sawyers, C. L., Kantarjian, H. M., Resta, D. J., Reese, S. F. Ford, J. M. et al. (2001) Activity of a specific inhibitor of the bcr-abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N Engl J Med, 344, pp. 1038-1042.
38. Kantarjian, H. M., Cortes, J., O'Brien, S., Giles, F. J., Albitar, M. Rios, M. B. et al. (2002) Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positivechronic myelogenous leukemia in blast phase. Blood, 99, pp. 3547-3553.
39. Sawyers, C. L., Hochhaus, A., Feldman, E., Goldman, J. M., Miller, C. B. Ottmann, O. G. et al. (2002) Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: Results of a phase II study. Blood, 99, pp. 3530-3539.
40. Fruehauf, S., Topaly, J., Buss, E. C., Fischer, T., Ottmann, O. G. Emmerich, B. et al. (2007) Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer, 109, pp. 1543-1549.
41. Towatari, M., Yanada, M., Usui, N., Takeuchi, J., Sugiura, I. Takeuchi, M. et al. (2004) Combination of intensive chemotherapy and imatinib can rapidly induce high-quality complete remission for a majority of patients with newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia. Blood, 104, pp. 3507-3512.
42. De Labarthe, A., Rousselot, P., Huguet-Rigal, F., Delabesse, E., Witz, F. and Maury, S. (2007) Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood, 109, pp. 1408-1413.
43. O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W. Mestan, J. et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res, 65, pp. 4500-4505.
44. Tokarski, J. S., Newitt, J. A., Chang, C. Y., Cheng, J. D., Wittekind, M. Kiefer, S. E. et al. (2006) The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res, 66, pp. 5790-5797.
45. Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G., Lin, H. Arlinghaus, R. et al. (2003) BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood, 101, pp. 690-698.
46. Donato, N. J., Wu, J. Y., Stapley, J., Lin, H., Arlinghaus, R. Aggarwal, B. B. et al. (2004) Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res, 64, pp. 672-677.
47. Wu, J., Meng, F., Kong, L. Y., Peng, Z., Ying, Y. Bornmann, W. G. et al. (2008) Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase. J Natl Cancer Inst, 100, pp. 926-939.
48. Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J. Paquette, R. et al. (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med, 354, pp. 2531-2541.
49. Cortes, J., Rousselot, P., Kin, D-W, Ritchie, E., Hamerschlak, N. Coutre, S. et al. (2007) Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood, 109, pp. 3207-3213.
50. Weisberg, E., Manley, P., Mestan, J., Cowan-Jacob, S., Ray, A. and Griffin, J. D. (2006) AMN107 (nilotinib): A novel and selective inhibitor of BCR-ABL. Br J Cancer, 94, pp. 1765-1769.
51. Kantarjian, H., Giles, F., Wunderle, L., Bhalla, K., O'Brien, S. Wassmann, B. et al. (2006) Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Eng J Med, 354, pp. 2542-2551.
52. Le Coutre, P, Giles, F. J., Apperley, J., Ottmann, O. G., Larson, R. A. Haque, A. et al. (2008) Nilotinib in accelerated phase chronic myelogenous leukemia patients with imatinib-resistant or -intolerance: update of a phase 2 study. J Clin Oncol, 26, p. 7050a.
53. Nicolini, F. E., Alimena, G., Al-Ali, H-K, Zaritskey, A. Y., Shen, Z. Jootar, S. et al. (2008) Expanding nilotinib access in clinical trials study in adult patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase, accelerated phase, or blast crisis: Updated safety analysis. J Clin Oncol, 26, p. 7059a.
54. Jabbour, E., Hochhaus, A., le Coutre, P, Rosti, G., Bhalla, K. N. Haque, A. et al. (2008) Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myelogenous leukemia in chronic or accelerated phase. J Clin Oncol, 26, p. 7063a.
55. Gambacorti-Passerini, C., Kantarjian, H., Baccarani, M., Porkka, K., Turkina, A. Zaritskey, A. Y. et al. (2008) Bosutinib demonstrates clinical activity and is well-tolerated among patients with AP and BP CML and Ph+ ALL. J Clin Oncol, 26, p. 7049a.
56. Quintas-Cardama, A., Kantarjian, H., Garcia-Manero, G., O'Brien, S., Faderl, S. Ravandi, F. et al. (2007) A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma, 48, pp. 283-289.
57. Oki, Y., Kantarjian, H. M., Gharibyan, V., Jones, D., O'Brien, S. Verstovsek, S. et al. (2007) Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia. Cancer, 109, pp. 899-906.
58. Abruzzese, E., Alimena, G., le Coutre, P, Bhalla, K. N., Ossenkoppele, G. J. Haque, A. et al. (2008) Nilotinib in chronic myelogenous leukemia patients who failed prior imatinib and dasatinib therapy: Updated results of an open-label phase II study. J Clin Oncol, 26, p. 7055a.
59. Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., Paquette, R. L. Kuriyan, J. et al. (2002) Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell, 2, pp. 117-125.
60. Branford, S., Rudzki, B., Lynch, K. and Hughes, T. (2005) Pre-imatinib factors can be used to define the risk of BCR-ABL mutations for patients with CML in chronic phase and identify a minority who should have regular mutation screening. Blood (ASH Annual Meeting Abstracts), 106, p. 1079.
61. Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F. Poerio, A. et al. (2006) Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: By the GIMEMA working party on chronic myeloid leukemia. Clin Cancer Res, 12, pp. 7374-7379.
62. Hochhaus, A., Erben, P., Ernst, T. and Mueller, M. C. (2007) Resistance to targeted therapy in chronic myelogenous leukemia. Semin Hematol, 44:1, pp. 15-24.
63. O'Dwyer, M. E., Mauro, M. J., Blasdel, C., Farnsworth, M., Kurilik, G. Hsieh, Y. C. et al. (2004) Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with imatinib mesylate. Blood, 103, pp. 451-455.
64. O'Dwyer, M. E., Mauro, M. J., Kurilik, G., Mori, M., Balleisen, S. Olson, S. et al. (2002) The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood, 100, pp. 1628-1633.
65. Cortes, J. E., Talpaz, M., Giles, F., O'Brien, S., Rios, M. B. Shan, J. et al. (2003) Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood, 101, pp. 3794-3800.
66. Verma, D., Kantarjian, H., Estrov, Z., Garcia-Manero, G., Koller, C., Borthakur, G. and Cortes, J. (2007) Survival outcomes for patients with chronic myeloid leukemia with clonal evolution treated with 2nd generation tyrosine kinase inhibitors. Blood, 110, p. 2949.
67. Deininger, M. W., Cortes, J., Paquette, R., Park, B., Hochhaus, A. Baccarani, M. et al. (2007) The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer, 110, pp. 1509-1519.
68. Terre, C., Eclache, V., Rousselot, P., Imbert, M., Charrin, C. Gervais, C. et al. (2004) Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia, 18, pp. 1340-1346.
69. Kovitz, C., Kantarjian, H., Garcia-Manero, G., Abruzzo, L. V. and Cortes, J. (2006) Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood, 108, pp. 2811-2813.
70. Leis, J. F., Stepan, D. E., Curtin, P. T., Ford, J. M., Peng, B. and Schubach, S. (2004) Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571). Leuk Lymphoma, 45, pp. 695-698.
71. Bujassoum, S., Rifkind, J. and Lipton, J. H. (2004) Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy. Leuk Lymphoma, 45, pp. 401-403.
72. Senior, K. (2003) Gleevec does not cross blood-brain barrier. Lancet Oncol, 4, p. 198.
73. Porkka, K., Koskenvesa, P., Lundan, T., Rimpilainen, J., Mustjoki, S. Smykla, R. et al. (2008) Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood, 112, pp. 1005-1012.
74. Aichberger, K. J., Herndlhofer, S., Agis, H., Sperr, W. R., Esterbauer, H. Rabitsch, W. et al. (2007) Liposomal cytarabine for treatment of myeloid central nervous system relapse in chronic myeloid leukaemia occurring during imatinib therapy. Eur J Clin Invest, 37, pp. 808-813.
75. Hansen, J. A., Gooley, T. A., Martin, P. J., Appelbaum, F., Chauncey, T. R. Clift, R. A. et al. (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med, 338, pp. 962-968.
76. McGlave, P. B., Shu, X. O., Wen, W., Anasetti, C., Nademanee, A. Champlin, R. et al. (2000) Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program. Blood, 95, pp. 2219-2225.
77. Oehler, V. G., Gooley, T., Snyder, D. S., Johnston, L., Lin, A. Cummings, C. C. et al. (2007) The effect of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood, 109, pp. 1782-1789.
78. Carpenter, P. A., Synder, D. S., Flowers, M ED, Sanders, J. E., Gooley, T. A. Martin, P. J. et al. (2007) Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood, 109, pp. 2791-2793.
79. Olavarria, E., Siddique, S., Griffiths, M. J., Avery, S., Byrne, J. L. and Piper, K. P. (2007) Post-transplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood, 110, pp. 4614-4617.